16

Retinal vein occlusion (RVO) is the most common vascular retinopathy after diabetic retinopathy. It includes central retinal vein occlusions (CRVOs) and branch retinal vein occlusions (BRVOs). Macular edema (ME) marks a major turning point in the progression of the disease in that it is the main cause of reduced visual acuity. Scientific advances have been able to shed light on the main agent involved in the mechanisms of modulation of vascular permeability, namely, vascular endothelial growth factor (VEGF) which is found in significant quantities in the vitreous cavity and aqueous humor of patients with retinal microangiopathies, such as RVO. Thus, substances capable of counteracting angiogenic factors appear to be clearly relevant to the treatment of microangiopathies. In our current context, Bevacizumab is the most accessible anti-VEGF molecule, although it does not have marketing authorization (MA) for this indication. It is a recombinant humanized monoclonal antibody that selectively binds to VEGF, inhibiting its action. The study that we have assembled around this theme is a non-interventional, analytical, retrospective study compiled in our department involving 30 cases (32 eyes), spanning a period of 24 months. The results of our study showed an improvement in visual acuity of around 25 letters according to the Early Treatment Diabetic Retinopathy Study (ETDRS) scale, with a reduction in mean centro-foveolar thickness of 180 μm, 12 months after the 1st intravitreal injection of Bevacizumab. This study aims to highlight the effectiveness of Bevacizumab on visual acuity and macular thickness in macular edema secondary to retinal vein occlusion, and to dispel some of the mystery that still surrounds this pathology today.